Building a full-cycle intelligent chronic disease management benchmark! Fangzhou Health and Novo Nordisk sign MOU to jointly create a new health management ecosystem
On July 18, at the 3rd China International Industrial Chain Promotion Expo, Ark Healthcare (06086.HK), a leading AI and internet healthcare company, officially signed a memorandum of cooperation with Novo Nordisk, a global leader in biopharmaceuticals. Leveraging its AI application service scenarios and convenient pharmaceutical services, Ark Healthcare will collaborate with Novo Nordisk on projects focused on the management of serious chronic diseases such as diabetes and obesity.
Photo caption: Arkmed and Novo Nordisk signed a memorandum of cooperation on site
Dr. Xie Fangmin, Founder, Chairman, and CEO of Ark Healthcare, attended the signing ceremony together with Zhou Xiaping, Senior Vice President of Novo Nordisk and President of Greater China, to witness the signing of the Memorandum of Understanding.
Leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou Pharmaceutical will fully utilize its smart healthcare ecosystem and robust technological foundation to build a closed-loop, full-cycle health management service covering medication guidance, medication reminders, efficacy tracking, and health education. This initiative will shape a new ecological value chain in glucose control and weight management, comprehensively advancing the transition of diabetes and obesity care from "disease-centered" to "health-centered," and providing patients with higher-quality, more convenient one-stop services.
Xie Fangmin, Founder, Chairman and CEO of Ark Healthcare"We hope to collaborate with Novo Nordisk, a global leader in biopharmaceuticals, to explore the application of AI technology, overcome the pain points in traditional health management models, and provide innovative, digital, and intelligent benchmark solutions for global blood glucose and weight management."
Novo Nordisk Senior Vice President and President of Greater China, Xiaoping Zhou"Stating: 'As a global leading biopharmaceutical company, for over a century Novo Nordisk has been committed to driving change and combating serious chronic diseases, particularly diabetes and obesity. This collaboration leverages the strengths of both parties to integrate scientific prevention and treatment of chronic diseases with digital innovation, jointly enhancing awareness of diabetes and obesity, and fully realizing the concept of early screening, early diagnosis, and early treatment within smart healthcare scenarios.'"
Looking ahead, both parties are expected to continue exploring further innovative collaborations in the digital and intelligent transformation of the healthcare industry, bringing greater benefits to patients with serious chronic diseases and supporting the accelerated realization of the "Healthy China 2030" strategic goals.